Effects of rhLactoferrin on Chronic Inflammation in the Elderly
Status:
Completed
Trial end date:
2019-02-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate how recombinant human lactoferrin (rhLF) which is
a partially iron saturated form of lactoferrin produced and purified from rice grain may
improve mobility and memory in older adults with chronic inflammation. Lactoferrin, is a
known multifunctional protein, and has been shown to have anti-inflammatory effects. A
recombinant human version of this protein was recently developed and produced from rice. This
is now available from the Ventria Bioscience Company in a controlled, pharmaceutical grade
capsule. As part of this double blinded and randomized study, participants will take daily
dosages of recombinant human lactoferrin (rhLF) or its matched placebo; to measure the
effects of rhlactoferrin on chronic inflammation and its association with improving mobility
and memory over a 6 month time period. During the study all participants will be asked to
provide blood samples and will have physical and cognitive tests administered to them. By
measuring biomarkers in the blood as well as changes in physical and cognitive measures, the
investigators will gain an understanding of how rhlactoferrin may safely improve measures of
chronic inflammation in older adults. As well as a better understanding of whether it has the
potential to meaningfully influence important measures of physical and cognitive function
known to be influenced by Chronic Inflammation (CI).